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ABSTRACT  
Vaccines against oncoantigens halt early neoplastic lesions in several cancer-prone, 
genetically engineered mouse models, whereas their ability to prevent chemical 
carcinogenesis has not been explored. This is a significant issue since exposure to chemical 
mutagens is responsible for a substantial percentage of cancers worldwide. Here we show 
that the archetypal oncoantigen ERBB2 is transiently overexpressed in Syrian hamsters 
during the early stages of 7,12-dimethylbenz[α]anthracene (DMBA)-induced oral 
carcinogenesis. Repeated DNA vaccinations against ERBB2 significantly reduce the number, 
size and severity of oral lesions in a manner directly proportional to the anti-ERBB2 antibody 
response. These results support the prospects of vaccines as a fresh strategy in the 
management of individuals at risk for exposure to defined carcinogenic agents.
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INTRODUCTION 
Immunoprevention of tumors associated with microbial infections is expected to 
decrease the human tumor burden in the near future (1, 2). Vaccines against tumor antigens 
with a causal role in the promotion of carcinogenesis unrelated to infections (oncoantigens) 
(3) halt early neoplastic progression in several cancer-prone, genetically engineered mice due 
to their ability to target molecules with an essential role in tumor progression. They have a 
limited therapeutic potential, but are very effective in inhibiting the early stages of cancer. 
Whereas the potential of vaccines against oncoantigens to prevent tumors is being 
extensively studied in transgenic mouse models (4-7), their ability to interfere with the 
progression of chemical carcinogenesis is still mostly unexplored. Chemical pollutants and 
especially polycyclic aromatic hydrocarbons are widespread environmental contaminants 
responsible for many animal and human cancers (8).  
The membrane tyrosine kinase receptor ERBB2 is an archetypal oncoantigen overexpressed 
by several carcinomas generally characterized by a more aggressive course in both humans 
and animals, whereas its expression is low or absent in normal adult tissues (9-12). Anti-
ERBB2 vaccination protects against and cures mice with transplantable ERBB2+ tumors (13), 
and inhibits one of the most aggressive, metastasizing and lethal ERBB2-driven mammary 
carcinogenesis in transgenic mice (14) for the whole of their natural lifespan (15). In cancer 
patients, anti-ERBB2 vaccines elicit both antibody and cell-mediated response to ERBB2, 
while monoclonal (mAb) anti-ERBB2 antibodies display a significant therapeutic activity (16).  
Spurred by Sun et al.’s observation of the expression of ERBB2 during oral 
carcinogenesis induced by a non-heterocyclic polycyclic aromatic hydrocarbon (7,12-
dimethylbenz[α]anthracene, DMBA) in hamsters (17), we first evaluated the intensity and 
persistence of ERBB2 expression in a large group of random-bred hamsters during the 
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DMBA-induction of oral squamous cell carcinomas. This is one of the best characterized 
animal models of chemical carcinogenesis and closely recapitulates several features of the 
development of the corresponding human cancer (17-20). While ERBB2 is expressed only 
transiently during the early stages of DMBA carcinogenesis, we found that repeated boosts 
with a DNA vaccine anti-ERBB2 resulted in significant reduction of the number, size and 
severity of oral lesions in function of the anti-ERBB2 antibody titer. This finding may open a 
fresh scenario in the management of individuals exposed to a defined carcinogenic agent. 
 
MATERIALS AND METHODS  
 
Hamsters  
One hundred and six, six-week-old male, random-bred Syrian golden hamsters (Mesocricetus 
auratus, Charles River Laboratories, Calco, Italy), of about 100 g were maintained in specific 
pathogen-free conditions with a 12 h light–dark cycle, and with rodent chow and tap water ad 
libitum. Their right cheek pouch was painted three times a week with a 0.5% solution of 
DMBA dissolved in mineral oil (Sigma-Aldrich, Milan, Italy) applied with No. 4 paintbrush. The 
amount of carcinogen and treatment delivered to each animal was rendered quite uniform by 
using the ‘‘wiped-brush’’ method (19, 20). The unilateral formation of tumors allowed the 
animals to eat and swallow normally. 
 
Experimental plan 
In the first experiment, thirty-six hamsters were treated with DMBA for twelve weeks (Fig. 1A). 
At the end of every week, three hamsters were randomly sacrificed. Pouches and major 
organs were inspected and processed for histopathological analysis.  
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In the next experiment, seventy hamsters were first electroporated in both tibial muscles with 
50 µg of EC-TM plasmids coding the extracellular and transmembrane domains of rat ERBB2 
receptor, or with the empty pcDNA3 plasmids (21) twenty-one and seven days before starting 
DMBA carcinogenesis induction (day 0), and then every three weeks (Fig. 2A). Every week 
hamsters were anesthetized and the pouches everted. The first onset of visible lesions, and 
their number/single cheek pouch (multiplicity) was evaluated. Each lesion was measured in 
the two perpendicular diameters, classified and photographed. The type, multiplicity and size 
of the lesions at the end of DMBA-induction period were used to elaborate an overall 
pathological score (PS) for each hamster (22). PS 0 for no lesions; 1 for each preneoplastic 
lesion; 2 for an exophytic lesion less than 1 mm in diameter; 3 to 8 for each exophytic lesion 
larger than 1 mm proportionally to the increase of their mean diameter. At the end of twelve 
weeks' carcinogenesis induction blood was collected, hamsters were sacrificed and their 
pouches and major organs were processed for histopathological and molecular analyses. All 
experimental procedures were approved by the Institutional and National Animal Care 
Committee. 
 
Histology and immunohistochemistry  
Specimens were fixed in methyl-Carnoy’s fluid or 10% neutralized formaldehyde solution and 
embedded in paraffin, or fixed in pyridoxal phosphate and embedded in OCT. Four µm thick 
sections were stained with hematoxylin-eosin, or processed for immunohistochemistry. 
Several commercial anti-ERBB2 mAb were assayed for their ability to recognize Syrian 
hamster ERBB2 receptor on cheek pouches with and without preneoplastic and neoplastic 
lesions (c-erbB-2/Her2/neu Ab-17 and c-erbB-2/Her2/neu, LabVision, Fremont, CA; c-erbB-2 
Oncoprotein and HercepTest™, Dako Cytomation, Milan, Italy; Her 2/ErbB2, Cell Signaling, 
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Beverly MA; Neu(C-18) and Neu(9G6), SantaCruz, Santa Cruz, CA). Positive controls were 
microarray slides of human ERBB2+ mammary carcinomas and the appropriate isotype 
antibody for each primary antibody used. Since the best results on formalin fixed-paraffin 
embedded samples were obtained with the anti-ERBB2 mAb c-erbB-2 Oncoprotein, this mAb 
was used for all the studies reported here. For p63 staining, the anti-human p63 protein clone 
4A4 (Dako) was used at 1:50 dilution. 
 
Western Blot analysis 
Samples from normal epithelium, preneoplastic lesions and exophytic lesions were 
homogenized in RIPA buffer (Cell Signaling Technology, Pero, Italy). Forty μg of total proteins 
were separated on an 8% SDS–polyacrylamide gel, and electrotransferred to a Hybond-C 
nitrocellulose membrane (Amersham Pharmacia Biotech, Little Chalfont, UK). Western blot 
analysis was performed with the mouse Ab-3 mAb (Oncogene Research Products, 
Cambridge, MA, USA). The membrane was then exposed to the appropriate horseradish 
peroxidase-conjugate secondary antibody (1:5000) (Sigma) for 1 h at room temperature, and 
labeled bands were detected with a commercial chemiluminescence kit (Immun-Start, Bio-
Rad Hercules, CA, USA). Images of the immunoreactive bands were acquired with a Kodak 
Image Station 440CF (Kodak, Rochester, NY, USA). 
 
Plasmid electroporation 
pcDNA3 vectors coding the extracellular and transmembrane domains of rat HER-2 receptor 
(EC-TM) and the empty control plasmid (pcDNA3) were produced and used as we have 
previously described in detail (21). Briefly, anesthetized hamsters were electroporated by 
injecting 50 µg of plasmids in 40 µl of 0.9% NaCl supplemented with 6 mg/ml polyglutamate 
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into both tibial muscles. Electric pulses were applied by two electrodes placed on the shaved 
skin around the injection area covered with a conducting gel. Two square-wave 25 ms, 375 
V/cm pulses were generated by a T820 electroporator (BTX, San Diego, CA, USA). Hamsters 
were electroporated twenty-one and seven days before starting DMBA carcinogenesis 
induction (day 0), and then every three weeks.  
 
Antibody response 
The titer of anti-ERBB2 antibodies was assessed by flow cytometry with BALB/c NIH-3T3 
fibroblasts stably co-transfected with the wild-type rat ERBB2, mouse class I H-2Kd and B7.1 
genes (BALB/c NIH 3T3-NKB cells) (23). FITC-conjugated goat antibodies specific for 
hamster IgG heavy and light chains (ImmunoKontact, Abingdon, Oxon, UK) were used to 
detect bound primary antibody. Normal hamster serum was used as a negative control, and 
the Ab-4 mAb (Oncogene Research Products, Cambridge, MA, USA) was the positive control. 
Cells were resuspended in PBS-azide-BSA containing 1 mg/ml of propidium iodide to gate out 
dead cells, and evaluated with a CyAn ADP (Dako Cytomation, Heverlee, Belgium) and the 
Summit 4.3 (Dako Cytomation) software. The specific 3T3-NKB binding potential of the sera 
was calculated as follows: ([% positive cells with test serum] [fluorescence mean]) × serum 
dilution (23). A total of 104 viable cells were analyzed in each evaluation. 
 
Statistical analysis 
Differences in antibody titer, multiplicity and diameters of lesions were analyzed with 
one-way analysis of variance. Those in the % of lesion-free hamsters were evaluated with the 
Log-Rank (Mantel-Cox) test and Fisher’s exact test. Differences in the number of fast and 
intermediate progressors were evaluated with Fisher’s exact test, whereas distribution within 
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groups was assessed with Pearson’s chi-square test. Differences in the number of exophytic 
lesions classed in different stage groups were compared with the non-parametric Mann–
Whitney Rank Sum test. All analyses were performed with GraphPad Prism version 5.00 for 
Windows (GraphPad Software, San Diego, CA, USA) with P < 0.05 as the significance cut-off. 
 
RESULTS 
ERBB2 expression throughout the DMBA-induced carcinogenesis 
The right cheek pouch of random-bred Syrian hamsters was painted three times weekly for 
twelve consecutive weeks with a 0.5% solution of DMBA in mineral oil (Fig. 1A). Three 
randomly chosen hamsters were sacrificed at the end of every week to follow the lesion 
development. Direct inspection of the cheek pouch surface (Fig. 1B) disclosed early 
enlargement of blood vessels in the painted area, followed at week 4 by inflammation 
associated with a rough surface. Around week 7, preneoplastic lesions became evident, 
sometimes as corrugated or verrucous leukoplakias. Hereafter exophytic lesions appeared 
and grew. Histological analysis (Fig. 1C) revealed that, within four weeks of DMBA induction, 
a moderate inflammatory reaction was developed as well as the hyperkeratotic feature of the 
epithelium. At week 7, foci of intraepithelial dysplasia became evident, while the epithelium 
displayed hyperkeratotic and acanthotic features. Subsequently dysplastic lesions grew into 
intraepithelial carcinoma. The resulting exophytic lesions consisted of finger-like papillae 
covered by a multilayered epithelium with features of moderately differentiated, in situ 
keratinized squamous cell carcinoma, sometime progressing to invasive squamous cell 
carcinoma. ERBB2 expression was evaluated throughout the induction (Fig. 1D and E): it was 
absent or scarcely present in the basal layer of normal and inflamed epithelium, but became 
markedly enhanced in the hyperkeratotic and acanthotic epithelia of the leukoplakia patches, 
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then almost disappeared in intraepithelial and invasive carcinomas. Preliminary data in few 
specimens from different patients (3 normal mucosae, 6 dysplastic lesions, and 5 carcinomas) 
suggest that a similar pattern of transient ERBB2 expression is also a feature of human oral 
preneoplastic/dysplastic lesions and squamous cell carcinoma (Supplementary Fig. S1). 
 
DMBA-induced carcinogenesis is hampered by anti-ERBB2 DNA vaccine 
To determine whether induction of the immune response against ERBB2 impairs a 
chemically-driven carcinogenesis, forty hamsters were electroporated every three weeks with 
EC-TM plasmids (21, 24). Thirty control hamsters were electroporated with the empty 
pcDNA3 plasmids. In both groups, DMBA induction of cheek pouch carcinogenesis began 
one week after the second electroporation (Fig. 2A). The kinetics of the occurrence of 
preneoplastic lesions was delayed in hamsters electroporated with EC-TM (Fig. 2B) and their 
multiplicity was reduced (Fig. 2C). Ten weeks after the beginning of DMBA induction, 
preneoplastic lesions were present in 60% (18/30) of control hamsters, but in only 32.5% 
(13/40) (p = 0.029) of those electroporated with EC-TM plasmids. In these hamsters, lesion 
multiplicity was less than half (0.62 + 0.15) of that of the controls (1.21 + 0.23) (P = 0.029). 
The assessment of preneoplastic lesions was ended at week 10 since most of them then 
progressed to exophytic lesions. At week 11, in fact, all 30 control hamsters displayed one or 
more exophytic lesions (Fig. 2D). By contrast, 6 of the 40 hamsters electroporated with EC-
TM (15%) (P = 0.034) remained free from exophytic lesions until week 12, when the 
experimental observation was ended. At this time, both the multiplicity (Fig. 2E) and the size 
(Fig. 2F) of the exophytic lesions were lower in EC-TM electroporated hamsters than in the 
controls.  
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Pathological stage of the exophytic lesions. 
Since in human head and neck squamous cell carcinomas, overexpression of p63, a member 
of the p53 family, is widely associated with poor prognosis (25, 26), we assessed p63 
expression in DMBA-induced lesions. Post-mortem pathological analysis showed that 
exophytic lesions of control hamsters displayed a diffuse p63 expression, while in the smaller 
lesions of EC-TM electroporated hamsters it was confined to basal and parabasal cell layers 
(Fig. 2G and H).  
The presence of smaller exophytic lesions is of special interest since size is directly 
associated with a more advanced stage. Most of the smaller lesions were lined by dysplastic 
epithelium with areas of severe dysplasia, whereas the larger lesions were invasive, 
advanced squamous cell carcinomas. A pathological survey performed at the end of the 
experiment on 35 randomly chosen EC-TM and control hamsters displaying exophytic lesions 
showed that both dysplastic lesions and carcinomas were less advanced in those 
electroporated with EC-TM (Supplementary Table S1). 
 
EC-TM immunized hamsters with the highest anti-ERBB2 antibody titer display 
hampered DMBA-carcinogenesis.  
At the end of the induction the PS was assessed for each hamster by evaluating the stage of 
its cheek lesions. It was significantly lower in EC-TM immunized hamsters than in the controls 
(P < 0.001). The analysis was deepened by setting two arbitrary thresholds at PS 2.5 and 5.0 
to classify hamsters as fast (PS > 5), intermediate (2.5 < PS < 5), and slow progressors (PS < 
2.5) (Fig. 3A). The controls were mainly fast progressors (73%) and the other 27% were 
intermediate. No animal had a PS less than 2.5 at the sacrifice. Of the EC-TM electroporated 
hamsters, 27% were fast progressors, 25% intermediate progressors and 48% slow 
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progressors with a very indolent progression (Fig. 3B). Anti-ERBB2 antibody titer was nearly 
undetectable in the controls, whereas in the EC-TM group it was inversely correlated (P < 
0.05) to the PS value (Fig. 3C). Moreover, the time of appearance of exophytic lesions, the 
number of preneoplastic and exophytic lesions, and their diameters were markedly different 
between fast and slow progressors in the EC-TM hamsters (Supplementary Fig. S2). 
 
DISCUSSION 
These findings show that vaccination against an oncoantigen significantly impairs the 
progression of chemically induced oral carcinogenesis. The incidence, number and size of 
preneoplastic and exophytic lesions are reduced and their pathological stage is less 
advanced in hamsters immunized against ERBB2. Moreover, at the end of the observation 
period, all control hamsters displayed exophytic lesions and invasive cancer whereas six 
(15%) of the ERBB2 immunized hamsters were still free from lesions. 
This protection is proportional to the intensity of anti-ERBB2 antibody response induced by 
the vaccine even if the titers in the slow progressors ranged from very low titers to very high. 
The presence of slow progressors with low anti-ERBB2 antibody titers can probably be 
ascribed to the induction of a stronger cytotoxic response against ERBB2+ target cells. Since 
our population was random-bred, vaccination was expected to elicit markedly different levels 
of cytotoxicity. The collaboration of antibody and cell-mediated cytotoxic responses in 
protection against ERBB2+ tumors has been clearly documented (27). We have previously 
shown that electroporation of the EC-TM plasmid in hamsters elicits a protective anti-ERBB2 
antibody and cell-mediated cytotoxic response against ERBB2+ transplantable tumors (21). In 
the present study, a similar cytotoxic response was also elicited in the few ERBB2 vaccinated 
hamsters tested (data not shown). However, when random-bred hamsters are used, 
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differences in major histocompatibility antigens markedly affect the efficacy of T-cell killing of 
ERBB2+ target cell lines, and so the cytotoxic response of all the immunized hamsters was 
not compared.  
Admittedly, random-bred hamsters are not a suitable model for fine dissection of the immune 
mechanisms activated by the vaccine because of the lack of specific reagents and 
standardized procedures. However, the immune mechanisms elicited by anti-ERBB2 DNA 
vaccine have been extensively studied in various mouse models of ERBB2 cancer. In wild-
type BALB/c mice, the electroporation of EC-TM plasmids elicits an antibody and CD8+ T cell 
mediated immune response (28). In BALB/c mice transgenic for the ERBB2 oncogene (BALB-
neuT mice), it inhibits the progression of ERBB2-driven carcinogenesis. However, in these 
mice vaccine elicits mostly, if not only, an antibody response (14, 29). The lack of cell-
mediated cytotoxicity is due to the absence of CD8+ T cells reacting with rat ERBB2 with high 
avidity. In BALB-neuT mice, a form of split-tolerance allows anti-ERBB2 vaccine to induce 
only a CD4+ T cell activation and a significant antibody response to ERBB2 (30, 31). The 
protection elicited in these mice against autochthonous carcinomas rests on the multiple 
direct and indirect antitumor activities of vaccine-induced anti-ERBB2 antibodies.  
The antibody response to ERBB2 is especially effective because ERBB2 is both the target 
antigen of the EC-TM vaccine and a membrane-exposed receptor regulating cell growth (3). 
EC-TM-induced anti-ERBB2 antibodies impede the progression of ERBB2 carcinogenesis by 
blocking the proliferation of ERBB2+ tumor cells (29). Inhibition of ERBB2 receptor 
dimerization and induction of internalization and recycling prevent the transduction of 
activating signals (14, 24). EC-TM induced antibodies reduce the basal level of Akt 
phosphorylation in ERBB2+ cells without impairing PI3K enzymatic activity, and induce an 
increase of PTEN phosphatase activity correlated with reduced PTEN tyrosine 
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phosphorylation (32). They also indirectly affect tumor growth by mediating antibody-
dependent cell-mediated cytotoxicity (23).  
ERBB2 is a tumor associated molecule with a causal role in cancer progression. However, it 
is a self tolerated molecule and triggering a response to it has to circumvent central and 
peripheral tolerance (4, 15). Data in mice (24) and hamsters (21) have shown that EC-TM 
plasmid electroporation is an effective way to break tolerance. However, the antibody 
response thus induced is short-lived and frequent electroporations are required for a 
sustained control of carcinogenesis (24). This requirement is also evident in human patients 
vaccinated against tumor-associated antigens (33). In the present study, EC-TM plasmids 
electroporations repeated every four weeks kept anti-ERBB2 antibody levels stable during the 
twelve weeks of the DMBA carcinogenesis induction (not shown).   
The kinetics of the occurrence of preneoplastic lesions is markedly delayed in ERBB2 
vaccinated hamsters. Their progression to exophytic lesions, and their growth is also delayed. 
Necroscopic pathological observations show that both the progression of preneoplastic 
lesions to severe dysplasia and that of squamous cell carcinomas to frankly invasive cancer 
are hampered. Our work on transgenic mice electroporated with EC-TM plasmids had shown 
that the immunity elicited hampered the progression of neoplastic lesions while it was unable 
to reduce the growth of existing lesions (15, 24, 31). This issue has not been directly 
addressed in the present experiments. However, it is probable that the effects we observed 
on more advanced lesions in ERBB2 vaccinated hamsters are mostly the result of immune 
inhibition of the progression of earlier stages of the lesions.   
Present data extend to specific immunity previous findings showing that IL-12-boosted innate 
immunity effectively counteracts 3-methylcholanthrene carcinogenesis in mice through the 
release of cytokines and boosting of innate immunity mechanisms (34). They also endorse 
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the pioneering work of Thorbecke's group on vaccination with tumor cells (35) and on the 
central role of antibody (36) in preventing DMBA induced sarcomas in chickens. 
Since vaccines against oncoantigens are especially effective in inhibiting the progression of 
early stages of cancer (4), characterization of oncoantigens overexpressed during such 
stages along with refinement of vaccines to make them able to trigger innate and adaptive 
immune mechanisms, may form a fresh strategy for the management of individuals at high 
risk of cancer following exposure to a specific carcinogenic agent. 
However, caution is needed in directly assessing the significance of these results to humans. 
While the hamster cheek pouch model mimics many aspects of human cancer (e.g. multi-
stage development, pathological and histological features, molecular alterations) it has some 
limitations (e.g. the human mouth does not have a similar structure and chemical induction is 
very quickly elicited in hamsters by a high carcinogen dose) (18). Moreover, studies 
addressing the expression of ERBB2 in human preneoplastic and neoplastic oral cavity 
lesions have provided inconclusive and conflicting results (37-43). Whether ERBB-2 is driving 
the early stage of carcinogenesis, and at which stage this driving role acquires critical 
significance are not yet clearly defined. The pathological evidence in supplementary Figure 1 
suggests that the controversy on ERBB2 overexpression in human head and neck cancer 
may be partly due to its transient overexpression in critical stages of carcinogenesis. 
However, the samples analyzed are too few as a source of definitive conclusions. 
Nevertheless, the question of whether the ERBB2 expression in our model really mimics the 
human scenario, while important, is not a central issue of this study. Although ERBB2 
expression in the human head and neck cancer is debated, our data suggest that an immune 
response against an oncoantigen, even if it is apparently transiently expressed only in a few 
stages of carcinogenesis, may hamper the progression of mutagen-induced carcinogenesis. 
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The differences we observed between control and ERBB2 immunized hamsters are relatively 
small and thus may seem of limited clinical significance. However, vaccine-induced protection 
was observed against a continuous and prolonged chemical induction of oral cancer that in 
eleven weeks causes the onset of oral exophytic lesions in all control hamsters. As evinced 
by necroscopic analysis at the twelfth week, most of them were lesions characterized by a 
severe grade of dysplasia or were invasive carcinomas (Supplementary Table S1). In this fast 
and aggressive model, our multiple protection data acquire a special significance since they 
provide a proof of concept on the potential of vaccination in hampering chemical 
carcinogenesis. In a slower and less aggressive chemical induction, more refined vaccines 
and more effective vaccination schedules may lead to a stronger immunity, and the protection 
afforded may acquire a true clinical significance. The experimental evidence that 
pharmacological (17) and vaccine-induced interference with an oncogene product impairs 
mutagen induced carcinogenesis provides a further demonstration on the efficacy of 
preventive maneuvers for cancer prevention and may spur the search for fresh immune, 
pharmacological and combined strategies to treat healthy persons at risk, for whom no active 
therapeutic option exists at present. 
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CAPTIONS  
 
Figure 1: Stages of DMBA-induced carcinogenesis . A, weeks when the right cheek pouch 
mucosa was painted with DMBA (blue arrows). B, appearance of DMBA painted area: 
enlargement of blood vessels (B1); inflammation and whitish granular appearance (B2); foci 
of leukoplakia (B3 and B4), exophytic lesions (B5 and B6). C, histological examination: 
moderate (C1) and marked inflammatory reaction (C2); focal dysplasia (C3 and C4); 
moderately differentiated, in situ (C5) and invasive squamous cell carcinoma (C6). D, 
immunohistochemistry of ERBB2 expression: absent or scarcely present (D1 and D2); 
markedly evident in hyperplastic and dysplastic epithelia (D3 and D4); poorly evident and only 
persisting in limited areas of the squamous cell carcinomas (D5 and D6). E, Western blot 
analysis of ERBB2 expression evaluated on three hamster cheek pouches. Data were 
normalized with actin expression. (Original magnification: C1-2, D1-2 x400 and C3-6, D3-6 
x200).  
 
Figure 2: Anti-ERBB2 DNA vaccine hampers DMBA-induced carcinogenesis. A, starting two 
weeks before the cheek pouch painting with DMBA, hamsters were electroporated every 
three weeks with pcDNA3 or EC-TM plasmids (red arrows). Percent of hamsters free of 
prenenoplasric lesions (B) and their multiplicity (C). Percent of hamsters free of exophytic 
lesions (D), their multiplicity (E) and their size (E). Expression of p63 in large exophytic and 
hyperkeratotic lesions from hamsters electroporated with empty pcDNA3 (G) or EC-TM (H) 
plasmids. * P < 0.05; ** P < 0.01; *** P < 0.001. (Original magnification: G and H x100). 
 
Figure 3: EC-TM immunized hamsters with the highest anti-ERBB2 antibody titer display 
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hampered DMBA-carcinogenesis. A, PS is lower in EC-TM immunized hamsters than the 
controls electroporated with empty pcDNA3 plasmids (P < 0.001). The 2.5 and 5 PS 
thresholds divide hamsters into fast (gray), intermediate (empty), and slow (green) 
progressors. B, The number of fast progressors is significantly lower among the hamsters 
immunized with EC-TM plasmids (P < 0.001). Slow progressors were only present among 
EC-TM electroporated hamsters. C, Among EC-TM electroporated hamsters the slow 
progressors (green square) displayed the highest titer of anti-ERBB2 antibodies, while those 
classed as fast progressors (gray square) the lowest (P < 0.01). * P < 0.05; ** P < 0.01; *** P 
< 0.001. 
  
 



